The main transporter shown to mediate gemcitabine uptake in human cell lines is hENT1 (SLC29A1), and clinical correlation studies have shown that low expression of hENT1 in pancreatic adenocarcinoma is linked with poor outcomes of gemcitabine treatment [14,15,16]. This evidence concerns the gene SLC29A1 and pancreatic adenocarcinoma.